Tappei et al. [9] found that NPC1L1-overexpressing human colorectal cancer cells exhibited higher uptake of phylloquinone than controls, and that NPC1L1 inhibitor ezetimibe inhibited phylloquinone uptake in a dose-dependent manner. Here, NPC1L1 is linked to colorectal cancer.